Bastiaan Jeroen van der Baan - 17 Jun 2022 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role: Director
Signature: /s/ Bastiaan van der Baan
Issuer symbol: LIXT
Transactions as of: 17 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Jul 2022, 06:14:34 UTC
Next filing: 05 Jan 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LIXT	Options to Purchase Common Stock	Award	$0	+250,000		$0.000000	250,000	17 Jun 2022	Common	250,000	$0.7400	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	In connection with the Reporting Person's appointment as a director of the Issuer, the Issuer granted to the Reporting Person options to purchase 250,000 shares of the Issuer's Common Stock exercisable for a period of five years at an exercise price of $0.74 vesting 50% on the date of the grant and the remaining 50% vesting 12.5% beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued service.

Content

In connection with the Reporting Person's appointment as a director of the Issuer, the Issuer granted to the Reporting Person options to purchase 250,000 shares of the Issuer's Common Stock exercisable for a period of five years at an exercise price of $0.74 vesting 50% on the date of the grant and the remaining 50% vesting 12.5% beginning in the quarter immediately subsequent to the date of the grant until fully vested, subject to continued service.